This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Revance Therapeutics 향후 성장

Future 기준 점검 1/6

Revance Therapeutics은 연간 수입과 매출이 각각 60.7%와 19.2% 증가할 것으로 예상되고 EPS는 연간 61%만큼 증가할 것으로 예상됩니다.

핵심 정보

60.7%

이익 성장률

60.98%

EPS 성장률

Pharmaceuticals 이익 성장	11.1%
매출 성장률	19.2%
향후 자기자본이익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	22 Jan 2025

최근 향후 성장 업데이트

Recent updates

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Sep 26

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Jun 20

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Mar 04

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Feb 29

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Nov 10

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Aug 10

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Jun 14

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Apr 17

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Jan 02

이익 및 매출 성장 예측

NasdaqGM:RVNC - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	497	-9	131	85	5
12/31/2026	415	-31	55	26	8
12/31/2025	333	-102	-35	-24	8
12/31/2024	264	-168	-108	-53	8
9/30/2024	257	-303	-195	-191	N/A
6/30/2024	251	-304	-209	-201	N/A
3/31/2024	240	-325	-221	-213	N/A
12/31/2023	234	-324	-223	-217	N/A
9/30/2023	204	-292	-210	-204	N/A
6/30/2023	179	-337	-214	-211	N/A
3/31/2023	153	-341	-204	-202	N/A
12/31/2022	133	-356	-197	-194	N/A
9/30/2022	109	-274	-214	-208	N/A
6/30/2022	99	-263	-210	-203	N/A
3/31/2022	90	-274	-216	-208	N/A
12/31/2021	78	-281	-232	-222	N/A
9/30/2021	63	-297	-247	-239	N/A
6/30/2021	47	-303	-250	-242	N/A
3/31/2021	29	-292	-218	-210	N/A
12/31/2020	15	-282	-183	-179	N/A
9/30/2020	4	-249	-152	-150	N/A
6/30/2020	0	-209	-129	-126	N/A
3/31/2020	0	-186	-141	-138	N/A
12/31/2019	0	-159	-109	-106	N/A
9/30/2019	1	-155	-108	-104	N/A
6/30/2019	3	-146	-103	-97	N/A
3/31/2019	4	-143	-112	-105	N/A
12/31/2018	4	-143	-111	-104	N/A
9/30/2018	3	-138	-107	-102	N/A
6/30/2018	1	-136	N/A	-98	N/A
3/31/2018	0	-128	N/A	-85	N/A
12/31/2017	0	-121	N/A	-95	N/A
9/30/2017	0	-111	N/A	-80	N/A
6/30/2017	0	-99	N/A	-73	N/A
3/31/2017	0	-97	N/A	-65	N/A
12/31/2016	0	-89	N/A	-60	N/A
9/30/2016	0	-85	N/A	-63	N/A
6/30/2016	0	-86	N/A	-62	N/A
3/31/2016	0	-78	N/A	-58	N/A
12/31/2015	0	-73	N/A	-56	N/A
9/30/2015	0	-66	N/A	-48	N/A
6/30/2015	0	-60	N/A	-47	N/A
3/31/2015	0	-57	N/A	-47	N/A
12/31/2014	0	-63	N/A	-55	N/A
9/30/2014	1	-49	N/A	-60	N/A
6/30/2014	1	-48	N/A	-54	N/A
3/31/2014	1	-38	N/A	-62	N/A

애널리스트 향후 성장 전망

수입 대 저축률: RVNC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: RVNC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: RVNC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: RVNC 의 수익(연간 19.2%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: RVNC 의 수익(연간 19.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: RVNC의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/02/05 03:24
종가	2025/02/05 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Revance Therapeutics, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Maris	BMO Capital Markets Equity Research
Louise Chen	Cantor Fitzgerald & Co.
Donald Ellis	Citizens JMP Securities, LLC

This company has been acquired

Revance Therapeutics 향후 성장

Future 기준 점검 1/6

핵심 정보

최근 향후 성장 업데이트

No longer forecast to breakeven

Price target decreased by 17% to US$13.58

Forecast to breakeven in 2026

Price target decreased by 18% to US$16.33

Price target decreased by 14% to US$23.17

Price target decreased by 9.9% to US$25.67

Recent updates

Revance Therapeutics Common Stock to Delist from Nasdaq Global Select Market

Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from NASDAQ Composite Index

Crown Laboratories, Inc. completed the acquisition of Revance Therapeutics, Inc. (NasdaqGM:RVNC).

Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from NASDAQ Biotechnology Index

Teoxane S.A. cancelled the acquisition to acquire all remaining stake in Revance Therapeutics, Inc. (NasdaqGM:RVNC).

Teoxane S.A. submitted a proposal to acquire all remaining stake in Revance Therapeutics, Inc. (NasdaqGM:RVNC) for $360 million.

Holzer & Holzer, Llc Files Class Action Lawsuit Against Revance Therapeutics, Inc

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Crown Laboratories, Inc. entered into a merger agreement to acquire Revance Therapeutics, Inc. (NasdaqGM:RVNC) for approximately $720 million.

Revance Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 17% to US$13.58

Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Revance Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Forecast to breakeven in 2026

Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting

Insufficient new directors

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Revance Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Price target decreased by 18% to US$16.33

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Revance Therapeutics, Inc. Announces Executive Changes

Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology

Price target decreased by 14% to US$23.17

Price target decreased by 9.9% to US$25.67

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

New minor risk - Profitability

Revance Therapeutics, Inc. Reports Consolidated Impairment for the Quarter Ended September 30, 2023

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Price target decreased by 18% to US$29.25

Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics

Price target decreased by 7.1% to US$33.67

Revance Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Price target decreased by 9.0% to US$36.25

Consensus EPS estimates fall by 13%

Senior VP notifies of intention to sell stock

U.S. FDA Approves First Therapeutic Indication for Revance's Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CEO & Director notifies of intention to sell stock

Revance Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CEO & Director notifies of intention to sell stock

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

CEO & Director notifies of intention to sell stock

CFO & Principal Accounting Officer notifies of intention to sell stock

CEO & Director recently sold US$2.4m worth of stock

Forecast to breakeven in 2025

CEO & Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO & Principal Accounting Officer notifies of intention to sell stock

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

CFO & Principal Accounting Officer notifies of intention to sell stock

CEO & Director recently sold US$2.2m worth of stock

No longer forecast to breakeven

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

CFO & Principal Accounting Officer notifies of intention to sell stock